Brief: Active Biotech Releases Tasquinimod Study Results For RRMM
09/06/2025 15:55
June 9 (Reuters) - Active Biotech AB publ ACTI.ST: RELEASES TASQUINIMOD STUDY RESULTS FOR RRMM TASQUINIMOD WELL TOLERATED IN COMBINATION WITH IRD 47% CLINICAL BENEFIT RATE IN TOTAL COMBINATION COHORT Source text: ID:nMFN41wW5T Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million